Obinutuzumab Doubles Remission Duration in Relapsed, Indolent Non-Hodgkin Lymphoma - European Medical Journal

Obinutuzumab Doubles Remission Duration in Relapsed, Indolent Non-Hodgkin Lymphoma

Oncology

Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgkin lymphoma (NHL). Among patients for whom rituximab therapy no longer provided benefit, the average duration of remission was 29.2 months after receiving the new combination vs. 14 months after bendamustine alone. The trial was stopped early based on these encouraging results.

Presented by Laurie Helen Sehn, MDCM, MPH, BC Cancer Agency, Vancouver, Canada, at ASCO 2015.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now